Skip to main content

Table 3 Multivariate survival analysis of LINE-1 methylation level and clinicopathological parameters with respect to overall survival

From: Tumoral LINE-1 hypomethylation is associated with poor survival of patients with intrahepatic cholangiocarcinoma

  Hazard ratio (95% C.I.) P-value Hazard ratio (95% C.I.) P-value
LINE-1 methylation levela Q3, Q4 (n = 86)     
Q1, Q2 (n = 86) 2.643 (1.443–4.482) 0.002 2.248 (1.205–4.196) 0.011
N staging pN0 (n = 133)     
pN1 (n = 39) 2.211 (1.176–4.157) 0.014 2.749 (1.491–5.066) 0.001
T staging    0.025   0.130
pT1 (n = 48) Reference   Reference  
pT2 (n = 52) 1.943 (0.979–3.855) 0.058 0.555 (0.211–1.458) 0.232
pT3 (n = 47) 0.941 (0.420–2.105) 0.882 0.363 (0.121–1.091) 0.071
pT4 (n = 25) 0.433 (0.123–1.523) 0.192 0.216 (0.053–0.889) 0.034
Gross type    0.076   0.064
Mass forming (n = 141) Reference   Reference  
Periductal infiltrative (n = 8) 0 0.964 0 0.972
Intraductal growth (n = 18) 0.134 (0.018–0.971) 0.047 0.123 (0.017–0.910) 0.040
Mixed (n = 5) 2.672 (0.827–8.638) 0.101 2.878 (0.854–9.694) 0.088
Lymphatic emboli Absent (n = 102)     
Present (n = 70) 2.519 (1.429–4.438) 0.001 2.720 (1.168–6.337) 0.020
Perineural invasion Absent (n = 118)     
Present (n = 54) 0.386 (0.181–0.822) 0.014 0.373 (0.162–0.860) 0.021
Differentiation    0.083   0.638
Well (n = 23) Reference    
Moderate (n = 94) 9.405 (1.283–68.943) 0.027   
Poor (n = 55) 9.671 (1.290–72.518) 0.027   
  1. aRegardless of whether adjuvant and/or neoadjuvant therapy was included or not in the multivariate analysis, the hazard ratio of LINE-1 methylation level did not change